2026-04-18T06:10:13Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/128122025-10-24T10:28:44Zcom_2072_378070com_2072_378040col_2072_378092

Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors Harrington, Kevin Kitano, Shigehisa Parkes, Eileen Moreno, Irene Alonso-Casal, Guzman Gambardella, Valentina Institut Català de la Salut [Harrington K] The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK. [Kitano S] Japanese Foundation for Cancer Research, Tokyo, Japan. [Gambardella V] INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Valencia, Spain. [Parkes EE] Department of Oncology, University of Oxford, Churchill Hospital, Oxford, UK. [Moreno I] START Madrid, CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Alonso G] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Quimioteràpia combinada Càncer - Immunoteràpia Posologia ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada PD-1 antibody; Cancer; Immunotherapy Anticuerpo PD-1; Cáncer; Inmunoterapia Anticòs PD-1; Càncer; Immunoteràpia BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies. Clinical Trial number: NCT05471856 This article was funded by Boehringer Ingelheim International GmbH. 2025-03-21T09:31:00Z 2025-03-21T09:31:00Z 2025-01-16 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Harrington K, Kitano S, Gambardella V, Parkes EE, Moreno I, Alonso G, et al. Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors. Futur Oncol. 2025 Jan 16;21(2):195-200. 1744-8301 http://hdl.handle.net/11351/12812 10.1080/14796694.2024.2441107 39817655 001398428300001 http://hdl.handle.net/11351/12812 eng Future Oncology;21(2) https://doi.org/10.1080/14796694.2024.2441107 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Taylor & Francis Scientia